Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patients

被引:50
作者
Stefani, Alessandro [1 ]
Alifano, Marco [1 ]
Bobbio, Antonio [1 ]
Grigoroiu, Madalina [1 ]
Jouni, Rami [1 ]
Magdeleinat, Pierre [1 ]
Regnard, Jean-Francois [1 ]
机构
[1] Univ Paris 05, Dept Thorac Surg, Hop Hotel Dieu, F-75004 Paris, France
关键词
STAGE-IIIA N2; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM SURVIVAL; PREOPERATIVE CHEMOTHERAPY; ENDOBRONCHIAL ULTRASOUND; SURGICAL RESECTION; NEEDLE ASPIRATION; SURGERY; THERAPY; RADIOTHERAPY;
D O I
10.1016/j.jtcvs.2010.02.018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The role of surgery in patients with N2 non-small cell lung cancer is debated. The aim of this study was to evaluate the results of surgical resection after induction chemotherapy. Methods: We retrospectively reviewed the cases of patients with N2 non-small cell lung cancer who underwent neoadjuvant chemotherapy followed by resection between 2001 and 2007. They all had tumors deemed resectable. Results: One hundred seventy-five patients entered the study. Most of them received 2 or 3 cycles of chemotherapy (81%), in all cases platinum-based regimens. Chemotherapy response rate was 62%. Operations included 96 lobectomies/bilobectomies and 79 pneumonectomies. Complete resection rate was 94%, and perioperative mortality was 4.5%. A pathologic mediastinal downstaging was found in 39% of patients. Overall median survival time and 5-year survival were 34.7 months and 30%, respectively. Survival was affected by clinical response (median survival time 51 months and 5-year survival 42% for responders versus 19 months and 10% for nonresponders) and by nodal downstaging (51 months and 45% versus 25% and 22%). In the group of responders, nondownstaged patients showed satisfying survival (median survival time 30 months, 5-year survival 30%). In the group of nonresponders, survival was unsatisfactory when a lobectomy was performed (median survival time 20 months, 5-year survival 13%) and poor in case of pneumonectomy (15 months and 6%). Multivariate analysis found 4 factors significantly affecting survival: clinical response, nodal downstaging, number of chemotherapy cycles, and histopathologic response. Conclusions: Surgery after chemotherapy could be effective for selected patients with N2 non-small cell lung cancer. Survival for responders is satisfactory, even in case of persistent N2 disease. Prognosis for nonresponders is disappointing. (J Thorac Cardiovasc Surg 2010;140:356-63)
引用
收藏
页码:356 / 363
页数:8
相关论文
共 26 条
  • [1] Test performance of endobronchial ultrasound and transbronchial needle aspiration biopsy for mediastinal staging in patients with lung cancer: systematic review and meta-analysis
    Adams, K.
    Shah, P. L.
    Edmonds, L.
    Lim, E.
    [J]. THORAX, 2009, 64 (09) : 757 - 762
  • [2] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
    Albain, Kathy S.
    Swann, R. Suzanne
    Rusch, Valerie W.
    Turrisi, Andrew T., III
    Shepherd, Frances A.
    Smith, Colum
    Chen, Yuhchyau
    Livingston, Robert B.
    Feins, Richard H.
    Gandara, David R.
    Fry, Willard A.
    Darling, Gail
    Johnson, David H.
    Green, Mark R.
    Miller, Robert C.
    Ley, Joanne
    Sause, Willliam T.
    Cox, James D.
    [J]. LANCET, 2009, 374 (9687) : 379 - 386
  • [3] CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805
    ALBAIN, KS
    RUSCH, VW
    CROWLEY, JJ
    RICE, TW
    TURRISI, AT
    WEICK, JK
    LONCHYNA, VA
    PRESANT, CA
    MCKENNA, RJ
    GANDARA, DR
    FOSMIRE, H
    TAYLOR, SA
    STELZER, KJ
    BEASLEY, KR
    LIVINGSTON, RB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) : 1880 - 1892
  • [4] Pneumonectomy after chemotherapy:: Morbidity, mortality, and long-term outcome
    Alifano, Marco
    Boudaya, Mohamed S.
    Salvi, Maurizio
    Collet, Jean-Yves
    Dinu, Carmen
    Camilleri-Broet, Sophie
    Regnard, Jean-Francois
    [J]. ANNALS OF THORACIC SURGERY, 2008, 85 (06) : 1866 - 1873
  • [5] Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications
    Andre, F
    Grunenwald, D
    Pignon, JP
    Dujon, A
    Pujol, JL
    Brichon, PY
    Brouchet, L
    Quoix, E
    Westeel, V
    Le Chevalier, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2981 - 2989
  • [6] Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial
    Betticher, DC
    Schmitz, SFH
    Tötsch, M
    Hansen, E
    Joss, C
    von Briel, C
    Schmid, RA
    Pless, M
    Habicht, J
    Roth, AD
    Spiliopoulos, A
    Stahel, R
    Weder, W
    Stupp, R
    Egli, F
    Furrer, M
    Honegger, H
    Wernli, M
    Cerny, T
    Ris, HB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) : 1752 - 1759
  • [7] Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival
    Bueno, R
    Richards, WG
    Swanson, SJ
    Jaklitsch, MT
    Lukanich, JM
    Mentzer, SJ
    Sugarbaker, DJ
    [J]. ANNALS OF THORACIC SURGERY, 2000, 70 (06) : 1826 - 1831
  • [8] Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients
    De Waele, Michele
    Serra-Mitjans, Mireia
    Hendriks, Jeroen
    Lauwers, Patrick
    Belda-Sanchis, Jose
    Van Schil, Paul
    Rami-Porta, Ramon
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2008, 33 (05) : 824 - 828
  • [9] Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer
    Depierre, A
    Milleron, B
    Moro-Sibilot, D
    Chevret, S
    Quoix, E
    Lebeau, B
    Braun, D
    Breton, JL
    Lemarié, E
    Gouva, S
    Paillot, N
    Bréchot, JM
    Janicot, H
    Lebas, FX
    Terrioux, P
    Clavier, J
    Foucher, P
    Monchâtre, M
    Coëtmeur, D
    Level, MC
    Leclerc, P
    Blanchon, F
    Rodier, JM
    Thiberville, L
    Villeneuve, A
    Westeel, V
    Chastang, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 247 - 253
  • [10] One hundred consecutive pneumonectornies after induction therapy for non-small cell lung cancer: An uncertain balance between risks and benefits
    Doddoli, C
    Barlesi, F
    Trousse, D
    Robitail, S
    Yena, S
    Astoul, P
    Giudicelli, R
    Fuentes, P
    Thomas, P
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 130 (02) : 416 - 425